MIRA PHARMACEUTICALS, INC. (MIRA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$4.8M
Cash & Equivalents
$1.2M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$39M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05236114 | GEMINI-NSCLC: NSCLC Biomarker Study | OTHER | Recruiting | 1,200 |
| NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P... | PHASE3 | Recruiting | 540 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-17 | 8-K | MIRA PHARMACEUTICALS, INC. (MIRA) (CIK 0001904286) - EX-99.1 | EDGAR |